Literature DB >> 31338185

Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up?

Antonella Nappi1, Alessandro Perrella2, Luca Rinaldi3, Antonio Izzi4, Rodolfo Punzi4, Luigi Elio Adinolfi3, Costanza Sbeglia2, Pasquale Bellopede2, Adelaide Maddaloni2, Nunzia Papa1, Micaela Spatarella1.   

Abstract

Entities:  

Keywords:  ADR; DAAs; HCC; HCV; antiviral; cirrhosis

Year:  2019        PMID： 31338185      PMCID： PMC6613921          DOI： 10.1136/ejhpharm-2019-001975

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN： 2047-9956


× No keyword cloud information.
  5 in total

1.  Adverse drug reactions: definitions, diagnosis, and management.

Authors:  I R Edwards; J K Aronson
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

Review 2.  The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.

Authors:  Bruno Roche; Audrey Coilly; Jean Charles Duclos-Vallee; Didier Samuel
Journal:  Liver Int       Date:  2018-02       Impact factor: 5.828

Review 3.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-06-06

4.  Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.

Authors:  Shaoman Yin; Laurie Barker; Jianglan Z White; Ruth B Jiles
Journal:  J Manag Care Spec Pharm       Date:  2019-02

5.  Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist.

Authors:  A Nappi; A Perrella; P Bellopede; A Lanza; A Izzi; M Spatarella; C Sbreglia
Journal:  Infect Agent Cancer       Date:  2017-02-07       Impact factor: 2.965
  5 in total
  2 in total

1.  Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database.

Authors:  Cristina Scavone; Annamaria Mascolo; Francesca Futura Bernardi; Maria Luisa Aiezza; Paola Saturnino; Gaia Morra; Margherita Simonelli; Marida Massa; Andrea Pomicino; Giuseppina Minei; Raffaella Pisapia; Micaela Spatarella; Ugo Trama; Gaspare Guglielmi; Annalisa Capuano; Alessandro Perrella
Journal:  Front Pharmacol       Date:  2022-03-29       Impact factor: 5.810

2.  Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C.

Authors:  Ponni V Perumalswami; Brooke Wyatt; Chip A Bowman; Krupa Patel; Anna Mageras; Sara C Lewis; Andrea D Branch
Journal:  Cancer Med       Date:  2022-03-09       Impact factor: 4.711
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.